Design and development of gemcitabine loaded chitosan cloaked polymeric nanoparticles: investigation of glioma cancer cytotoxicity and its apoptosis inductions

1. Ius T, Lombardi G, Baiano C, Berardinelli J, Romano A, Montemurro N, Cavallo LM, Pasqualetti F, Feletti A (2023) Surgical management of adult brainstem gliomas: a systematic review and meta-analysis. Curr Oncol 30:9772–978510.3390/curroncol30110709 ↗

2. Lee-Chang C, Lesniak MS (2023) Next-generation antigen-presenting cell immune therapeutics for gliomas. J Clin Investig. 133–145. https://doi.org/10.1172/JCI16344910.1172/JCI163449 ↗

3. Alshiekh Nasany R, de la Fuente MI (2023) Therapies for IDH-mutant gliomas. Curr Neurol Neurosci Rep 23(5):225–23310.1007/s11910-023-01265-3 ↗

4. Hsia T, Small JL, Yekula A, Batool SM, Escobedo AK, Ekanayake E, You DG, Lee H, Carter BS, Balaj L (2023) Systematic review of photodynamic therapy in gliomas. Cancers (Basel) 15:391810.3390/cancers15153918 ↗

5. Chen W, Yingtian X, Yang D, Wang P, Yan X, Zhu J, Cui D (2022) Preparation of liposomes coated superparamagnetic iron oxide nanoparticles for targeting and imaging brain glioma. Nano Biomed Eng. 14(1):16–33. https://doi.org/10.5101/nbe.v14i1.p71-8010.5101/nbe.v14i1.p71-80 ↗

6. Thenuwara G, Curtin J, Tian F (2023) Advances in diagnostic tools and therapeutic approaches for gliomas: a comprehensive review. Sensors 23:984210.3390/s23249842 ↗

7. Yang K, Wu Z, Zhang H, Zhang N, Wu W, Wang Z, Dai Z, Zhang X, Zhang L, Peng Y (2022) Glioma targeted therapy: insight into future of molecular approaches. Mol Cancer 21:3910.1186/s12943-022-01513-z ↗

8. Sharma A, Graber JJ (2021) Overview of prognostic factors in adult gliomas. Ann Palliat Med 10:86374–8687410.21037/apm-20-640 ↗

9. Śledzińska P, Bebyn MG, Furtak J, Kowalewski J, Lewandowska MA (2021) Prognostic and predictive biomarkers in gliomas. Int J Mol Sci 22:1037310.3390/ijms221910373 ↗

10. Mair MJ, Geurts M, van den Bent MJ, Berghoff AS (2021) A basic review on systemic treatment options in WHO grade II-III gliomas. Cancer Treat Rev 92:10212410.1016/j.ctrv.2020.102124 ↗

11. Youssef G, Miller JJ (2020) Lower grade gliomas. Curr Neurol Neurosci Rep 20:1–910.1007/s11910-020-01040-8 ↗

12. Fisher JP, Adamson DC (2021) Current FDA-approved therapies for high-grade malignant gliomas. Biomedicines 9:32410.3390/biomedicines9030324 ↗

13. Ding Z, Sigdel K, Yang L, Liu Y, Xuan M, Wang X, Gu Z, Wu J, Xie H (2020) Nanotechnology-based drug delivery systems for enhanced diagnosis and therapy of oral cancer. J Mater Chem B 8:8781–879310.1039/D0TB00957A ↗

14. Doroudian M, MacLoughlin R, Poynton F, Prina-Mello A, Donnelly SC (2019) Nanotechnology based therapeutics for lung disease. Thorax 74(10):965–976. https://doi.org/10.1136/thoraxjnl-2019-21303710.1136/thoraxjnl-2019-213037 ↗

15. Lin Y-X, Wang Y, Blake S, Yu M, Mei L, Wang H, Shi J (2020) RNA nanotechnology-mediated cancer immunotherapy. Theranostics 10:281–299. https://doi.org/10.7150/thno.3556810.7150/thno.35568 ↗

16. Samrat K, Krishna Murthy TP, Divyashri G, Hari Krishna R, Chandraprabha MN (2023) Nanotechnology: antidiabetics, antioxidant and anti-inflammatory. In: Mane RS, Sharma RP, Kanakdande AP (eds) Nanomaterials for sustainable development: opportunities and future perspectives. Springer, Singapore, pp 235–263. https://doi.org/10.1007/978-981-99-1635-1_810.1007/978-981-99-1635-1_8 ↗

17. Wang DK, Rahimi M, Filgueira CS (2021) Nanotechnology applications for cardiovascular disease treatment: current and future perspectives. Nanomed Nanotechnol Biol Med 34:102387. https://doi.org/10.1016/j.nano.2021.10238710.1016/j.nano.2021.102387 ↗

18. Ferrari M (2005) Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 5:161–17110.1038/nrc1566 ↗

19. Jiang J, Cui X, Huang Y, Yan D, Wang B, Yang Z, Chen M, Wang J, Zhang Y, Liu G, Zhou C, Cui S, Ni J, Yang F, Cui D (2024) Advances and prospects in integrated nano-oncology. Nano Biomed Eng 16(2):152–187. https://doi.org/10.26599/NBE.2024.929006010.26599/NBE.2024.9290060 ↗

20. Cheng L, Jin C, Lv W, Ding Q, Han X (2011) Developing a highly stable PLGA-mPEG nanoparticle loaded with cisplatin for chemotherapy of ovarian cancer. PLoS ONE 6:e25433–e25433. https://doi.org/10.1371/journal.pone.002543310.1371/journal.pone.0025433 ↗

21. Margiotta N, Savino S, Denora N, Marzano C, Laquintana V, Cutrignelli A, Hoeschele JD, Gandin V, Natile G (2016) Encapsulation of lipophilic kiteplatin Pt(IV) prodrugs in PLGA-PEG micelles. Dalt Trans 45:13070–13081. https://doi.org/10.1039/c6dt00763e10.1039/c6dt00763e ↗

22. Domínguez-Ríos R, Sánchez-Ramírez DR, Ruiz-Saray K, Oceguera-Basurto PE, Almada M, Juárez J, Zepeda-Moreno A, del Toro-Arreola A, Topete A, Daneri-Navarro A (2019) Cisplatin-loaded PLGA nanoparticles for HER2 targeted ovarian cancer therapy. Colloids Surf B Biointerfaces 178:199–207. https://doi.org/10.1016/j.colsurfb.2019.03.01110.1016/j.colsurfb.2019.03.011 ↗

23. Noble S, Goa KL (1997) Gemcitabine. Drugs 54:447–47210.2165/00003495-199754030-00009 ↗

24. Habib S, Singh M (2021) Recent advances in lipid-based nanosystems for gemcitabine and gemcitabine–combination therapy. Nanomaterials 11(3):597. https://doi.org/10.3390/nano1103059710.3390/nano11030597 ↗

25. Sanlıer SH, Yasa M, Cihnioglu AO, Abdulhayoglu M, Yılmaz H, Ak G (2015) Development of gemcitabine-adsorbed magnetic gelatin nanoparticles for targeted drug delivery in lung cancer. Artific Cells Nanomed Biotechnol. https://doi.org/10.3109/21691401.2014.100149310.3109/21691401.2014.1001493 ↗

26. Garg NK, Dwivedi P, Campbell C, Tyagi RK (2012) Site specific/targeted delivery of gemcitabine through anisamide anchored chitosan/poly ethylene glycol nanoparticles: an improved understanding of lung cancer therapeutic intervention. Eur J Pharm Sci 47(5):1006–1014. https://doi.org/10.1016/j.ejps.2012.09.01210.1016/j.ejps.2012.09.012 ↗

27. Awasthi N, Zhang C, Ruan W, Schwarz MA, Schwarz RE (2012) BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer. Mol Cancer Ther 11(12):2644–2653. https://doi.org/10.1158/1535-7163.MCT-12-044710.1158/1535-7163.MCT-12-0447 ↗

28. Melisi D, Garcia-Carbonero R, Macarulla T, Pezet D, Deplanque G, Fuchs M, Trojan J, Oettle H, Kozloff M, Cleverly A, Smith C, Estrem ST, Gueorguieva I, Lahn MMF, Blunt Al, Benhadji KA, Tabernero J (2018) Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. Br J Cancer 119(10):1208–1214. https://doi.org/10.1038/s41416-018-0246-z10.1038/s41416-018-0246-z ↗

29. Yang R, Shim W-S, Cui F-D, Gang Cheng X, Han Q-R, Kim D-D, Chung S-J, Shim C-K (2009) Enhanced electrostatic interaction between chitosan-modified PLGA nanoparticle and tumor. Int J Pharm 371(1–2):142–147. https://doi.org/10.1016/j.ijpharm.2008.12.00710.1016/j.ijpharm.2008.12.007 ↗

30. Fu S, Xia J, Wu J (2016) Functional chitosan nanoparticles in cancer treatment. J Biomed Nanotechnol 12:1585–160310.1166/jbn.2016.2228 ↗

31. Peers S, Montembault A, Ladavière C (2020) Chitosan hydrogels for sustained drug delivery. J Control Release 326:150–16310.1016/j.jconrel.2020.06.012 ↗

32. Jouybari MH, Hosseini S, Mahboobnia K, Boloursaz LA, Moradi M, Irani M (2019) Simultaneous controlled release of 5-FU, DOX and PTX from chitosan/PLA/5-FU/g-C3N4-DOX/g-C3N4-PTX triaxial nanofibers for breast cancer treatment in vitro. Colloids Surf B Biointerfaces 179:495–504. https://doi.org/10.1016/j.colsurfb.2019.04.02610.1016/j.colsurfb.2019.04.026 ↗

33. Rujiravanit R, Kruaykitanon S, Jamieson AM, Tokura S (2003) Preparation of crosslinked chitosan/silk fibroin blend films for drug delivery system. Macromol Biosci 3:604–61110.1002/mabi.200300027 ↗

34. Yen H, Young Y, Tsai T, Cheng K, Chen X, Chen Y, Chen C, Young J (2018) Positively charged gold nanoparticles capped with folate quaternary chitosan: synthesis, cytotoxicity, and uptake by cancer cells. Carbohydr Polym 183:140–15010.1016/j.carbpol.2017.11.096 ↗

35. Chen G, Zhao Y, Yuehua X, Zhu C, Liu T, Wang K (2020) Chitosan nanoparticles for oral photothermally enhanced photodynamic therapy of colon cancer. Int J Pharm 589:119763. https://doi.org/10.1016/j.ijpharm.2020.11976310.1016/j.ijpharm.2020.119763 ↗

36. Khoee S, Keivanshokouh A (2020) Anisotropic modification of SPIONs surface with thiol and alkyne groups for fabrication of poly (2-hydroxyethyl methacrylate)/polydopamine amphiphilic Janus nanoparticles via double-click reaction. Colloids Surf A Physicochem Eng Asp 597:124777. https://doi.org/10.1016/j.colsurfa.2020.12477710.1016/j.colsurfa.2020.124777 ↗

37. Nassir AM, Shahzad N, Ibrahim IAA, Ahmad I, Shadab M, Ain MR (2018) Resveratrol-loaded PLGA nanoparticles mediated programmed cell death in prostate cancer cells. Saudi Pharm J 26(6):876–885. https://doi.org/10.1016/j.jsps.2018.03.00910.1016/j.jsps.2018.03.009 ↗

38. Elkateb H, Tatham LM, Cauldbeck H, Niezabitowska E, Owen A, Rannard S, McDonald T (2020) Optimization of the synthetic parameters of lipid polymer hybrid nanoparticles dual loaded with darunavir and ritonavir for the treatment of HIV. Int J Pharm 588:119794. https://doi.org/10.1016/j.ijpharm.2020.11979410.1016/j.ijpharm.2020.119794 ↗

39. Delplace V, Couvreur P, Nicolas J (2014) Recent trends in the design of anticancer polymer prodrug nanocarriers. Polym Chem 5:1529–1544. https://doi.org/10.1039/c3py01384g10.1039/c3py01384g ↗

40. Alshetaili AS (2021) Gefitinib loaded PLGA and chitosan coated PLGA nanoparticles with magnified cytotoxicity against A549 lung cancer cell lines. Saudi J BiolSci 28(9):5065–5073. https://doi.org/10.1016/j.sjbs.2021.05.02510.1016/j.sjbs.2021.05.025 ↗

41. Zhang R, Qin X, Kong F, Chen P, Pan G (2019) Improving cellular uptake of therapeutic entities through interaction with components of cell membrane. Drug Deliv 26:328–34210.1080/10717544.2019.1582730 ↗

42. Suyana P, Nishanth Kumar S, Nimisha Madhavan BS, Kumar D, Nair BN, Peer Mohamed A, Warrier KGK, Hareesh US (2015) Reactive oxygen species (ROS) mediated enhanced anti-candidal activity of ZnS–ZnO nanocomposites with low inhibitory concentrations. RSC Adv 5(94):76718–76728. https://doi.org/10.1039/C5RA13316E10.1039/C5RA13316E ↗

43. Liu K, Liu P-c, Liu R, Xing W (2015) Dual AO/EB staining to detect apoptosis in osteosarcoma cells compared with flow cytometry. Med Sci Monit Basic Res 21:15–20. https://doi.org/10.12659/MSMBR.89332710.12659/MSMBR.893327 ↗

44. Fischer D, Li Y, Ahlemeyer B, Krieglstein J, Kissel T (2003) In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials 24(7):1121–1131. https://doi.org/10.1016/S0142-9612(02)00445-310.1016/S0142-9612(02)00445-3 ↗

45. Kamatchi TS, Subarkhan MKM, Ramesh R, Wang H, Małecki JG (2020) Investigation into antiproliferative activity and apoptosis mechanism of new arene Ru(ii) carbazole-based hydrazone complexes. Dalt Trans 49(32):11385–11395. https://doi.org/10.1039/D0DT01476A10.1039/D0DT01476A ↗

46. Jara MO, Catalan-Figueroa J, Landin M, Morales JO (2018) Finding key nanoprecipitation variables for achieving uniform polymeric nanoparticles using neurofuzzy logic technology, Drug Deliv. Transl Res 8:1797–1806. https://doi.org/10.1007/s13346-017-0446-810.1007/s13346-017-0446-8 ↗

47. Pannerec-Varna M, Ratajczak P, Bousquet G, Ferreira I, Leboeuf C, Boisgard R, Gapihan G, Verine J, Palpant B, Bossy E, Doris E, Poupon J, Fort E, Janin A (2013) In vivo uptake and cellular distribution of gold nanoshells in a preclinical model of xenografted human renal cancer. Gold Bull 46:257–265. https://doi.org/10.1007/s13404-013-0115-810.1007/s13404-013-0115-8 ↗

48. Zhao Q, Liu Y, Zhong J, Bi Y, Liu Y, Ren Z, Li X, Jia J, Yu M, Yu X (2019) Pristimerin induces apoptosis and autophagy via activation of ROS/ASK1/JNK pathway in human breast cancer in vitro and in vivo. Cell Death Discov 5:12510.1038/s41420-019-0208-0 ↗

49. Zhang W-Y, Wang Y-J, Fan D, He M, Yi-Ying G, Bai L, Yang L-L, Liu Y-J (2019) Evaluation of anticancer effect in vitro and in vivo of iridium(III) complexes on gastric carcinoma SGC-7901 cells. Eur J Med Chem 178:401–416. https://doi.org/10.1016/j.ejmech.2019.06.00310.1016/j.ejmech.2019.06.003 ↗

50. El-kott AF, Bin-Meferij MM (2018) Suppressive effects of capsaicin against N-nitrosomethylurea-induced mammary tumorigenesis in rats. Biomed Pharmacother 98:673–679. https://doi.org/10.1016/j.biopha.2017.12.03610.1016/j.biopha.2017.12.036 ↗

51. Li Y, Lin Z, Xu T, Wang C, Zhao M, Xiao M, Wang H, Deng N, Zhu B (2017) Delivery of VP1 siRNA to inhibit the EV71 virus using functionalized silver nanoparticles through ROS-mediated signaling pathways. RSC Adv 7:1453–1463. https://doi.org/10.1039/C6RA26472G10.1039/C6RA26472G ↗

52. Karuppaiya P, Satheeshkumar E, Tsay HS (2019) Biogenic synthesis of silver nanoparticles using rhizome extract of Dysosma pleiantha and its antiproliferative effect against breast and human gastric cancer cells. Mol Biol Rep 46:4725–4734. https://doi.org/10.1007/s11033-019-04917-110.1007/s11033-019-04917-1 ↗

53. Parker JP, Ude Z, Marmion CJ (2016) Exploiting developments in nanotechnology for the preferential delivery of platinum-based anti-cancer agents to tumours: Targeting some of the hallmarks of cancer. Metallomics 8:43–60. https://doi.org/10.1039/c5mt00181a10.1039/c5mt00181a ↗